Oncogene addiction and immunity: Clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene

Current Opinion in Oncology

Volumn 26, Issue 6, 2014, Pages 562-567

  Savas, Peter ^a   Caramia, Franco ^a   Teo, Zhi Ling ^a   Loi, Sherene ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Biomarkers; Breast cancer; HER2; Tumour infiltrating lymphocytes

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOMODULATING AGENT;

BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL DECISION MAKING; GENE OVEREXPRESSION; HUMAN; NONHUMAN; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; BREAST TUMOR; FEMALE; GENETICS; IMMUNOLOGY; MORTALITY; PROGNOSIS; PROTO ONCOGENE;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; PROGNOSIS;

EID: 84927591933     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000131     Document Type: Review

References (16)

1. Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094-1100.
2. Knight DA, Ngiow SF, Li M, et al. Host immunity contributes to the antimelanoma activity of BRAF inhibitors. J Clin Invest 2013; 123:1371-1381.
3. Rakha EA, Aleskandarany M, El-Sayed ME, et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 2009; 45:1780-1787.
4. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3:1355-1363.
5. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346-352.
6. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-113.
7. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Res 2013; 73 (Suppl 24); abstract S1-05.
8. Carey LA, Barry WT, Pitcher B, et al. Gene expression signatures in pre-and post-therapy specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J Clin Oncol 2014; 32 (5s); abstract 506.
9. Denkert C, Loibl S, Salat C, et al. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+BC). Cancer Res 2013; 73 (Suppl 24); abstract S1-06.
10. Gianni L, Bianchini G, Valagussa P, et al. Adaptive immune system and immune checkpoints are associated with response to pertuzumab and trastuzumab in the NeoSphere study. Cancer Res 2012; 72 (Suppl 24); abstract S6-7.
11. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit: results from the FinHER trial. Ann Oncol 2014; 25:1544-1550.
12. Perez EA, Thompson A, Anderson K, et al. Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. J Clin Oncol 2014; 32 (5s); abstract 509.
13. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214-218.
14. Brown SD, Warren RL, Gibb EA, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014; 24:743-750.
15. John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013; 19:5636-5646.
16. Verbrugge I, Hagekyriakou J, Sharp LL, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012; 72:3163-3174.